This site is intended only for healthcare professionals resident in the Republic of Ireland




Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up



AboutCurrent Migraine Treatment LimitationsMechanism of ActionEfficacyStudy DesignsAcute TreatmentPreventive TreatmentSafetyDosingResourcesPatient Resources

Currently not reimbursed by the HSE.

With VYDURA, dosing is simpleTreat and prevent with one orally dissolving tablet1

For acute treatment
To treat a migraine attack once it’s started, the recommended dose is
1 VYDURA 75 mg tablet, not more than once daily1

For preventive treatment

Take 1 VYDURA 75 mg tablet every other day1

For patients with CV disease or risk factors

  • VYDURA is not contraindicated in patients with cardiovascular (CV) risk factors or stable CV disease1,2

Co-administration of medications 

  • VYDURA can be co-administered with oral contraceptives3
No more than 1 tablet should be taken in a 24-hour period.1
See the safety profile Established SafetyLoading
Instruct patients to only remove VYDURA from the blister pack immediately before use

No titration needed1 

Patients can place VYDURA on or under their tongue, and it is designed to dissolve rapidly—no water needed

VYDURA 75 mg has Tmax of 1.5 hours1

Patients can go on with their day after taking a single tablet of 75 mg for either acute or preventive treatment

VYDURA 75 mg has a half-life of 11 hours1

Dosing considerations

VYDURA is not recommended for:

  • Patients with severe hepatic impairment1
  • Patients with end-stage renal disease (creatinine clearance <15 mL/min)1
  • Concomitant use with strong inhibitors of CYP3A41
  • Concomitant use with strong or moderate inducers of CYP3A41

Another dose of VYDURA within 48 hours should be avoided when it is concomitantly administered with moderate inhibitors of CYP3A4 (e.g., fluconazole).1

Inhibitors of P-gp and BCRP efflux transporters may increase plasma concentrations of rimegepant. Another dose of VYDURA within 48 hours should be avoided when it is concomitantly administered with strong inhibitors of P-gp.1

Medication-overuse headache (MOH)
Overuse of any type of medicinal products for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained, and treatment should be discontinued. The diagnosis of MOH should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of medicinal products for acute headache.1

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References:VYDURA (rimegepant) Summary of Product Characteristics. Data on File. RIM 130. Biohaven Pharmaceuticals Inc.Szkutnik-Fiedler D. Pharmacokinetics, pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and calcitonin-gene-related peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020;12(12):1180.

Legal Category: S1B
Further information is available upon request

PP-NNT-IRL-0019. June 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.


Copyright © 2024 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024